生物制药商Tempero Bio获得7000万美元B轮融资，推动TMP-301进入物质使用障碍的二期临床试验-动脉网

Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders

CISION 等信源发布 2025-03-24 19:00



可切换为仅中文







Funding will support two Phase 2 clinical trials in alcohol and cocaine use disorders

资金将支持针对酒精和可卡因使用障碍的两项二期临床试验。

Company has initiated Phase 2 study in alcohol use disorder and plans to initiate cocaine studies over the next year

公司已启动针对酒精使用障碍的第二阶段研究，并计划在未来一年内启动可卡因相关研究。

John Wagner M.D

约翰·瓦格纳医学博士

., Ph.D. to join as Chief Medical Officer

., 博士加入担任首席医学官

OAKLAND, Calif.

加利福尼亚州奥克兰市

，

March 24, 2025

2025年3月24日

/PRNewswire/ -- Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a

/PRNewswire/ -- Tempero Bio公司是一家临床阶段的生物制药公司，致力于开发治疗物质使用障碍的变革性疗法，今天宣布完成了

$70 million

7000万美元

Series B financing. The financing was led by 8VC with participation from Aditum Bio, Khosla Ventures, and other investors. The proceeds will be used to advance TMP-301 through two Phase 2 clinical trials for alcohol use disorder and cocaine use disorder, as well as Phase 3-enabling activities and preclinical studies for additional indications and formulations..

B轮融资。本轮融资由8VC领投，Aditum Bio、Khosla Ventures和其他投资者参投。所得资金将用于推动TMP-301通过两项针对酒精使用障碍和可卡因使用障碍的二期临床试验，以及三期支持活动和额外适应症与配方的临床前研究。

'Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year. We urgently need more effective treatments to help patients and families with these diseases,'

“物质使用障碍影响着4800万美国人，并导致每年超过10万人死亡。我们迫切需要更有效的治疗方法来帮助患有这些疾病的患者和家庭。”

said

说

Ricardo Dolmetsch

里卡多·多尔梅奇

, Ph.D., President and Chief Scientific Officer of Tempero Bio

博士，Tempero Bio公司总裁兼首席科学官

。

'TMP-301 is a novel therapy that helps prevent relapse by targeting the underlying biology of addiction. This financing will allow us to advance TMP-301 through key proof of concept phase 2 studies in humans.'

“TMP-301 是一种新型疗法，通过针对成瘾的潜在生物学机制来帮助预防复发。这笔资金将使我们能够推动 TMP-301 进入关键的概念验证第二阶段人体研究。”

TMP-301 for Substance Use Disorders

TMP-301 用于物质使用障碍

TMP-301 is a next-generation metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) designed to address neurobiological basis of addiction. It has shown promising results in preclinical models of alcohol, cocaine and opiate use disorders. TMP-301 has been evaluated in over 80 healthy volunteers in the Phase 1 setting with an acceptable safety and tolerability profile and has demonstrated robust receptor occupancy via positron emission tomography (PET) imaging..

TMP-301 是一种下一代代谢型谷氨酸受体 5 (mGluR5) 负变构调节剂 (NAM)，旨在解决成瘾的神经生物学基础。它在酒精、可卡因和阿片类药物使用障碍的临床前模型中显示出令人鼓舞的结果。TMP-301 已在一期临床试验中对 80 多名健康志愿者进行了评估，表现出可接受的安全性和耐受性，并通过正电子发射断层扫描 (PET) 成像显示了强大的受体占用率。

Advancing Clinical Development

推进临床开发

Tempero Bio has initiated two clinical studies to support TMP-301's development:

Tempero Bio 已启动两项临床研究以支持 TMP-301 的开发：

A Phase 2 trial evaluating TMP-301's efficacy and safety in patients with alcohol use disorder.

评估TMP-301在酒精使用障碍患者中的疗效和安全性的2期试验。

A drug-drug interaction (DDI) study assessing TMP-301 in individuals using cocaine. Research was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA057118.

评估TMP-301在使用可卡因个体中的药物相互作用（DDI）研究。本研究得到了美国国立卫生研究院下属的美国国家药物滥用研究所的支持，资助编号为U01DA057118。

A Phase 2 study in cocaine use disorder is planned following the completion of the DDI study.

一项针对可卡因使用障碍的二期研究计划在DDI研究完成后进行。

Addressing the Growing Addiction Crisis

应对日益严重的成瘾危机

The addiction crisis remains a significant public health challenge. The 2023 National Survey on Drug Use and Health reported that:

药物成瘾危机仍然是一个重大的公共卫生挑战。2023年全国药物使用与健康调查报告显示：

28 million Americans suffer from alcohol use disorder.

两千八百万美国人患有酒精使用障碍。

29 million Americans have a drug use disorder, with 7 million meeting criteria for both.

2900万美国人患有药物使用障碍，其中700万人同时符合两种标准。

1.3 million Americans have cocaine use disorder, with no FDA-approved medications available.

130万美国人患有可卡因使用障碍，尚无FDA批准的药物可用。

Despite these staggering numbers, nearly 13 million people sought treatment in 2023, reflecting the strong demand for better therapeutic options. Our mission is to provide better treatments for these patients.

尽管有这些惊人的数字，2023年仍有近1300万人寻求治疗，反映出对更好治疗方案的强烈需求。我们的使命是为这些患者提供更好的治疗。

John Wagner M.D

约翰·瓦格纳医学博士

., Ph.D. to join as Chief Medical Officer

., 博士加入担任首席医学官

Dr.

博士

John Wagner

约翰·瓦格纳

will be joining Tempero Bio as Chief Medical Officer. Dr. Wagner brings more than 20 years of drug development experience to his role, having successfully led over 150 first-in-human clinical trials and playing a pivotal role in bringing multiple blockbuster therapies to the market. Before joining Tempero Bio, Dr.

将加入Tempero Bio担任首席医学官。瓦格纳博士在药物开发方面拥有超过20年的经验，曾成功领导了150多项首次人体临床试验，并在多款重磅疗法推向市场的过程中发挥了关键作用。在加入Tempero Bio之前，瓦格纳博士。

Wagner served as Chief Medical Officer at Koneksa Health and Cygnal Therapeutics, held senior leadership positions at Takeda and Merck, and was a venture partner at Foresite Capital. Additionally, he currently serves as Editor-in-Chief of Clinical and Translational Science and holds an executive committee position with the Foundation for the National Institutes of Health Biomarkers Consortium..

瓦格纳曾在Koneksa Health和Cygnal Therapeutics担任首席医学官，在武田和默克担任高级领导职务，并且是Foresite Capital的创投合伙人。此外，他目前还担任《临床与转化科学》期刊的主编，并在国立卫生研究院生物标志物联盟基金会中担任执行委员会职位。

About Tempero Bio

关于Tempero生物

Tempero Bio is a clinical-stage biopharmaceutical company committed to developing innovative treatments for substance use disorders—chronic, relapsing brain diseases with limited pharmacologic solutions. The company is dedicated to advancing science-driven therapies that redefine treatment paradigms.

Tempero Bio是一家临床阶段的生物制药公司，致力于为物质使用障碍（一种慢性、复发性脑部疾病，药理学解决方案有限）开发创新疗法。该公司专注于推进以科学为驱动的治疗方法，重新定义治疗模式。

Tempero Bio is an Aditum Bio portfolio company. For more information, visit .

Tempero Bio 是 Aditum Bio 旗下的一家投资组合公司。欲了解更多信息，请访问。

www.temperobio.com

。

About Aditum Bio

关于Aditum Bio

Aditum Bio accelerates the development of high-impact therapies by in-licensing promising drug candidates, forming dedicated companies, and advancing them through clinical trials. Aditum Bio focuses on disease mechanisms where innovation can significantly improve public health. For more information, visit .

Aditum Bio通过授权有前景的候选药物、成立专门的公司并推动它们通过临床试验，加速了高影响力疗法的开发。Aditum Bio专注于那些创新可以显著改善公共健康的疾病机制。欲了解更多信息，请访问。

www.aditumbio.com

。

SOURCE Tempero Bio

来源：Tempero Bio

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &